Sandoz to Launch Generic Ozempic in Canada by 2026
Sandoz aims to disrupt Weight-Loss Market with Generic Ozempic in Canada
Swiss drugmaker Sandoz plans to launch a generic version of Novo Nordisk’s blockbuster diabetes drug Ozempic in Canada as early as 2026,perhaps shaking up the burgeoning weight-loss market.
Sandoz CEO Richard Saynor believes the existing generation of GLP-1 drugs, like semaglutide, the active ingredient in Ozempic, will remain in high demand despite the arrival of newer, more potent contenders from Novo and Eli Lilly.
“Everyone’s excited about second-generation GLP-1s, but current drugs are effective,” Saynor said in an interview. “I think these drugs are here to stay for a long time.”
Existing GLP-1 medications can lead to significant weight loss, often 10% to 15%, a level sufficient for most patients. Their effectiveness has been evident in the US, where they have made a noticeable dent in obesity rates.
Targeting a Booming Market
Canada, with its large population of adults struggling with obesity – one in three in 2022 – presents a lucrative chance for Sandoz. The country is the second-largest market for semaglutide globally.
Novo’s Wegovy, the weight-loss version of semaglutide, became available in Canada this year.While highly effective, its high price tag puts it out of reach for many. Sandoz aims to capitalize on this gap by offering a more affordable generic choice.
“If the price comes down from, I don’t know, a few hundred or a thousand dollars a month to a few tens of dollars a month, the patient population’s size is insane,” Saynor said.
Sandoz is prioritizing patient safety and is investing heavily in production to ensure its generic semaglutide meets the highest standards.
Patent Expiration Opens the Door
Wegovy’s patent on semaglutide expires in 2032 in the US and 2031 in Europe. Though, the patent expires earlier in China, in 2026, where local drugmakers are already gearing up to launch generic versions.
Sandoz’s move to enter the Canadian market with a generic Ozempic could signal the beginning of a price war in the weight-loss drug sector, potentially making these life-changing medications accessible to a wider range of patients.
Interview: Sandoz CEO on Disrupting the Weight-Loss Market with Generic Ozempic
NewsDirectory3.com: Dr. Saynor, sandoz is making waves by announcing plans to launch a generic version of Novo Nordisk’s Ozempic in Canada as early as 2026. What makes you confident in this move, considering the anticipation surrounding newer GLP-1 drugs from Novo adn Eli Lilly?
Richard Saynor, CEO Sandoz: While excitement surrounds the next generation of GLP-1s, we firmly believe the existing drugs, like semaglutide, remain highly effective.They deliver significant weight loss, frequently enough 10% to 15%, which is truly life-changing for many individuals.
ND3: You’re entering a market that already has Wegovy, Novo’s weight-loss version of semaglutide. How will Sandoz differentiate itself?
RS: Wegovy has shown remarkable results, but its price point makes it inaccessible to many.Sandoz aims to offer a more affordable generic option, possibly bringing this life-changing treatment within reach of a much broader patient population.
ND3: Can you elaborate on the potential impact of a lower-priced generic Ozempic in Canada, where obesity rates are significant?
RS: Canada has a large population struggling with obesity. If we can bring the cost down dramatically, from hundreds or even thousands of dollars a month to tens of dollars, the impact could be immense.
ND3: Sandoz is known for its commitment to quality. How will you ensure your generic semaglutide meets the highest standards?
RS: Patient safety is paramount. We’re investing heavily in our production processes to ensure our generic semaglutide meets the strictest quality standards.